NCT01076439

An Allergen BioCube (ABC) Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo

A Pilot Study Evaluating the Onset of Action of Fluticasone Furoate Nasal Spray and Olopatadine Nasal Spray Compared to Placebo Nasal Spray in Reducing Nasal Allergic Symptoms Following Ragweed Exposure in the Allergen BioCube (ABC)

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: ORA, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the onset of action of fluticasone furoate nasal spray compared to olopatadine nasal spray and placebo nasal spray in reducing nasal allergic signs and symptoms following ragweed exposure in the Allergen BioCube (ABC) after single dose administration and six consecutive days of treatment.

Conditions

• Allergic Rhinitis

Interventions

Type	Name	Description
DRUG	Fluticasone Furoate Nasal Spray	Fluticasone Furoate Nasal Spray: 110mcg QD
DRUG	Olopatadine Nasal Spray	Olopatadine Nasal Spray: 2660mcg BID
DRUG	Saline Nasal Spray	Placebo

Timeline

• First posted: 2010-02-26
• Last updated: 2012-02-22